Express News | NewAmsterdam Pharma Company NV - to Report Phase 3 Brooklyn Trial Data on July 29
Express News | NewAmsterdam Pharma to Announce Topline Data From Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)
Piper Sandler Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Board Reshuffles, Welcomes Industry Experts
Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors
Express News | NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib Plus Ezetimibe in Patients With Hefh and/or Ascvd or Ascvd Risk Factors
NewAmsterdam Pharma Files $400M Mixed Securities Shelf
Express News | NewAmsterdam Pharma Company NV Files for Mixed Shelf of up to $400 Mln - SEC Filing
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
NewAmsterdam Pharma(NAMS.US) Officer Buys US$86,308.5 in Common Stock
We Think NewAmsterdam Pharma (NASDAQ:NAMS) Can Afford To Drive Business Growth
Express News | NewAmsterdam Pharma Company NV: Patent Extends Obicetrapib's Ip Protection and Exclusivity Until July 2043
Express News | NewAmsterdam Pharma Company NV: Issuance of Composition of Matter Patent for Obicetrapib by United States Patent and Trademark Office
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)